Schering In Talks With Potential Partners For HDL Cholesterol Therapy
Schering and Merck’s cholesterol franchise continues to gain growth in terms of market share, but sequential sales of the combination therapy Vytorin fall flat.
Schering and Merck’s cholesterol franchise continues to gain growth in terms of market share, but sequential sales of the combination therapy Vytorin fall flat.